PeptideStack
5.2kquestions
20kanswers
220users

How much of GLP-1 weight loss is actually lean mass, and where does the "25%" figure come from?

Asked 11 Feb 2025Modified 15 months agoViewed 19k times
45

The claim that "about a quarter of what you lose on these drugs is muscle" gets repeated everywhere and I have never once seen it sourced. I am 14 weeks into tirzepatide, down 11.2 kg from 104.6 kg, and I would like to know what fraction of that is realistically lean tissue rather than guessing.

Three specific things I cannot resolve on my own:

  • Does the 25% figure come from an actual published body-composition substudy, or is it someone's back-of-envelope from total weight curves?
  • Is "lean mass" in those papers the same thing as muscle? My scale calls everything that is not fat "muscle" and I assume that is wrong.
  • Is the fraction different on a GLP-1 than on plain caloric restriction? The way it is talked about implies the drug specifically spares muscle, and I cannot find the head-to-head that would show that.

I do not have a baseline DEXA, which I now regret. I have a grip dynamometer reading from a physio appointment last year (right hand 51 kg) and nothing else objective. If the honest answer is "you cannot know retrospectively", I will take that, but I would still like to know what the trial data says the expected split is so I know whether what I am seeing in the mirror is normal or a problem.

lean-mass
lean-mass

Lean body mass as measured rather than assumed: what DEXA, BIA and air-displacement plethysmography each actually estimate, the body-composition…

164 questions
dexa
dexa

Dual-energy X-ray absorptiometry: what it measures, its precision limits, why hydration state and scan positioning move the numbers, and how to…

84 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
shareeditfollowflag
BN
askedbirk_nordahl20k2811 Feb 2025
Worth stating your protein intake and whether you lift, because the answer changes a lot depending on both. – two_two_micron 7 months ago
2Bodyweight scales that report "muscle mass" are extrapolating from a single impedance value. Do not treat that number as data. – k_szabo 9 months ago
add a comment

4 Answers

Accepted answer first, then by votes
118

Accepted answer

The 25% figure is real, but it is a derived ratio from one substudy rather than a measured constant, and it is routinely quoted with more authority than it deserves.

Where it comes from: the SURMOUNT-1 DEXA substudy reported that tirzepatide reduced total fat mass by about 33.9% and lean mass by about 10.9% in relative terms, which the authors summarised as roughly a 3:1 ratio of fat to lean tissue lost [1]. Convert the ratio to a share and you get the number everyone repeats:

fat : lean = 3 : 1
lean share = 1 / (3 + 1) = 0.25 = 25% of tissue lost

So "a quarter" is arithmetic performed on a single substudy's summary ratio. It is not wrong, but it is a central estimate from one drug, one dose range, one population, one scan modality.

What the substudies actually report

ProgrammeDEXA subgroupDurationReported body-composition findingImplied lean share of tissue lost
SURMOUNT-1 substudy~16072 weeksFat mass down ~33.9%, lean mass down ~10.9%; fat:lean ratio ~3:1~25%
STEP 1 substudy~14068 weeksFat mass fell as a proportion of body mass by ~3.5 percentage points; visceral fat down ~27%; lean mass share of body weight rose~30-40% depending on whether you use lean soft tissue or fat-free mass
Liraglutide vs exercise vs both195 randomised52 weeksLean mass preserved in the arms containing exercise; drug-alone arm lost lean massModality-dependent, not drug-dependent
Diet-only caloric restriction (historical benchmark)-3-12 monthsClassic figure for moderate deficits without training~20-30%
Roux-en-Y gastric bypass (historical benchmark)-12 monthsMuch larger absolute losses, similar proportion~25-30%

Notice what that table does not show: a GLP-1-specific muscle-sparing effect. The proportion is in the same band as diet-only restriction and the same band as surgery. The drug changes how much total tissue you lose and how easy the deficit is to sustain. It does not appear to change the fat-to-lean split much on its own. Anyone selling you the incretin as a muscle-sparing agent is over-reading the data.

Applying it to your 11.2 kg, with caveats

Naive application: 11.2 kg x 0.25 = 2.8 kg of lean soft tissue. That is the number you were probably expecting.

Two reasons the real figure is likely lower than that at week 14. First, the Forbes relationship: the fatter you are at baseline, the smaller the lean fraction of what you lose. At 104.6 kg you were almost certainly carrying enough fat mass to sit at the favourable end of that curve, which pushes you below 25%. Second, early loss is disproportionately water and glycogen, and DEXA scores both as lean soft tissue. The answer below works that arithmetic out; briefly, 2 kg of the "lean" in a fast first three months can be non-contractile.

My working estimate for someone in your position with adequate protein and any resistance stimulus is 1.2-2.0 kg of true lean soft tissue at week 14, of which some fraction is water. Without a baseline scan that is an estimate, not a measurement, and you should treat it as such.

edited 21 Apr 2025 by gradient_slope — added a caveat about sampling

shareimprove this answerflag
GS
answered · acceptedgradient_slope41k3818 Apr 2025
4The Forbes point is the one people skip. Lean fraction is not a constant, it is a function of starting fat mass. – coldpack_88 8 months ago
5Also worth noting the SURMOUNT-1 substudy was not powered to compare doses, so per-dose lean figures do not exist. – mateo_iglesias 1 days ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
124

Separate point from the accepted answer, and the one that trips up most people reading their own scans: "lean mass" on a DEXA report is lean soft tissue. It is everything that is not fat and not bone mineral. That includes skeletal muscle, but also organs, connective tissue, gut contents to some extent, blood volume, intracellular and extracellular water, and glycogen.

The water and glycogen component is not a rounding error during rapid loss. Work it through:

Trained-ish adult glycogen stores:
  liver          ~ 80-110 g
  skeletal muscle ~ 350-500 g
  total          ~ 430-610 g

Each gram of stored glycogen binds ~3 g of water:
  500 g glycogen x 3 g water = 1500 g water
  total glycogen + bound water = 500 + 1500 = 2000 g = 2.0 kg

So a person who goes from eating 250 g of carbohydrate a day to eating 90 g, which is what happens by accident when appetite falls off a cliff, can drop roughly 1.5-2.0 kg that DEXA will happily score as lost lean soft tissue. Zero contractile protein has been lost. Add sodium and aldosterone shifts on top and the first-month "lean loss" on a scan is substantially fluid.

The practical consequences:

  • A DEXA taken in the first 8-12 weeks of aggressive loss overstates lean tissue loss. Do not panic-interpret it.
  • The same distortion works in reverse when you stabilise. People who add carbohydrate back at maintenance "gain lean mass" on the next scan without training harder. That is refilling, not hypertrophy.
  • Scan under standardised conditions or the noise swamps the signal: same time of day, fasted, no training in the previous 24-48 hours, similar carbohydrate intake for the preceding 2-3 days, well hydrated but not water-loaded.

None of this means lean loss is imaginary. It means the first scan-to-scan delta is the least trustworthy one you will ever take, and that the signal only becomes clean once your intake and training have been stable for a couple of months.

shareimprove this answerflag
NO
answerednkem_obiora46k3830 Apr 2025
5The 3 g water per gram of glycogen figure is the one I use for explaining week-one drops and it lands every time. – RP_C18 5 months ago
add a comment
33

On your third question, whether the fraction differs from plain caloric restriction: the cleanest evidence that the drug is not the variable comes from the liraglutide-plus-exercise randomised trial, which ran four arms after a low-calorie induction phase: placebo, exercise alone, liraglutide alone, and both combined [2].

The headline everyone quotes is that the combination produced the largest fat loss. The part relevant to you is the body-composition breakdown: the arms that included supervised exercise held lean mass, and the drug-alone arm did not. The incretin did not confer protection by itself. The training did.

That is consistent with the broader literature on energy restriction going back decades: the two levers that reliably move the fat-to-lean split are (1) a mechanical loading stimulus and (2) adequate protein. Rate of loss is a weak third lever. The pharmacology is orthogonal to all three; what it changes is your ability to actually run the deficit.

Which reframes your question usefully. You are asking "how much muscle has the drug cost me". The better question is "what fraction of my loss is lean given that I am running a deficit of roughly X, eating Y grams of protein, and lifting Z times per week". Fill those in and the expected lean fraction ranges from near zero (well-fed, lifting, moderate deficit, high baseline fat mass) to 35-40% (very low intake, no loading, already lean, older). Same drug in both cases.

shareimprove this answerflag
DH
answeredDr_Wren_Halliday40k3827 Mar 2025
11

Practical answer to "I have no baseline": you cannot recover the counterfactual, so stop trying and start building forward data.

Get a DEXA now. It will not tell you what you lost, but it becomes the floor against which the next 6-12 months are measured, and that is the comparison that actually matters for whether you have a problem.

In the meantime you do have one useful retrospective anchor: that 51 kg grip reading. Re-test it on the same style of dynamometer, same hand, same posture, same instruction, best of three. Grip is a crude but genuinely predictive proxy for whole-body strength, and it is one of the first things to sag when someone is under-eating protein and under-recovering. If you are within a couple of kilograms of 51, whatever you lost has not meaningfully compromised force production. If you are at 40, that is worth acting on regardless of what any scan says.

Add two zero-cost functional markers you can repeat monthly: a timed five-repetition chair stand, and the load at which a familiar compound lift feels like a hard set of eight. Function is what lean mass is for. Track function.

The other retrospective anchor worth constructing, and it costs nothing: dig out any photograph of yourself from before week zero in which your arms and shoulders are visible, ideally in similar light. Photographs are terrible for quantifying fat and surprisingly informative about limb girth over a 10 kg change. Combine that with a tape measure at three fixed sites, mid-upper arm, mid-thigh and calf, taken at the same landmarks monthly from now on. Circumference is a crude proxy that conflates muscle and fat, but a thigh that is holding its circumference while your waist falls 8 cm is not a thigh that is being dismantled.

None of these substitutes for a scan. Together they will tell you within three months whether anything is actually going wrong, which is the only question that requires an answer.

shareimprove this answerflag
WC
answeredwren_calloway14k187 Apr 2025
8Grip retest protocol matters more than people think. Different dynamometer, different handle setting, different number. – ilaria_bertone 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.